Hiv-proteasehaemmere og interaktioner

Ulrik Stenz Justesen*, Kim Brøsen, Court Pedersen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Resumé

The protease inhibitors are a new class of drugs for the treatment of HIV infection. Results of treatment have proved beneficial to HIV positive patients, resulting in slower disease progression to aids and death. However the potential of drug interactions is high because of the drug-transporting P-glycoprotein and cytochrome P450 3A4-mediated metabolism. Administration of protease inhibitors may result in increased or decreased concentrations of co-administered drugs, and the plasma concentration of protease inhibitors may be affected by other drugs. It is possible to take advantage of the interactions by combining two protease inhibitors. Attention is drawn to the protease inhibitors and their possible interactions because of the advantages and disadvantages this implies. It is possible to monitor interactions by measuring plasma concentrations of the protease inhibitors.

OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind162
Udgave nummer35
Sider (fra-til)4677-4681
Antal sider5
ISSN0041-5782
StatusUdgivet - 28. aug. 2000

Fingeraftryk

Protease Inhibitors
Pharmaceutical Preparations
Cytochrome P-450 CYP3A
P-Glycoprotein
Drug Interactions
HIV

Citer dette

@article{54e8eb83a0b74ab3b9b8b91637b3dfa4,
title = "Hiv-proteasehaemmere og interaktioner",
abstract = "The protease inhibitors are a new class of drugs for the treatment of HIV infection. Results of treatment have proved beneficial to HIV positive patients, resulting in slower disease progression to aids and death. However the potential of drug interactions is high because of the drug-transporting P-glycoprotein and cytochrome P450 3A4-mediated metabolism. Administration of protease inhibitors may result in increased or decreased concentrations of co-administered drugs, and the plasma concentration of protease inhibitors may be affected by other drugs. It is possible to take advantage of the interactions by combining two protease inhibitors. Attention is drawn to the protease inhibitors and their possible interactions because of the advantages and disadvantages this implies. It is possible to monitor interactions by measuring plasma concentrations of the protease inhibitors.",
author = "Justesen, {Ulrik Stenz} and Kim Br{\o}sen and Court Pedersen",
year = "2000",
month = "8",
day = "28",
language = "Dansk",
volume = "162",
pages = "4677--4681",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "35",

}

Hiv-proteasehaemmere og interaktioner. / Justesen, Ulrik Stenz; Brøsen, Kim; Pedersen, Court.

I: Ugeskrift for Laeger, Bind 162, Nr. 35, 28.08.2000, s. 4677-4681.

Publikation: Bidrag til tidsskriftReviewForskningpeer review

TY - JOUR

T1 - Hiv-proteasehaemmere og interaktioner

AU - Justesen, Ulrik Stenz

AU - Brøsen, Kim

AU - Pedersen, Court

PY - 2000/8/28

Y1 - 2000/8/28

N2 - The protease inhibitors are a new class of drugs for the treatment of HIV infection. Results of treatment have proved beneficial to HIV positive patients, resulting in slower disease progression to aids and death. However the potential of drug interactions is high because of the drug-transporting P-glycoprotein and cytochrome P450 3A4-mediated metabolism. Administration of protease inhibitors may result in increased or decreased concentrations of co-administered drugs, and the plasma concentration of protease inhibitors may be affected by other drugs. It is possible to take advantage of the interactions by combining two protease inhibitors. Attention is drawn to the protease inhibitors and their possible interactions because of the advantages and disadvantages this implies. It is possible to monitor interactions by measuring plasma concentrations of the protease inhibitors.

AB - The protease inhibitors are a new class of drugs for the treatment of HIV infection. Results of treatment have proved beneficial to HIV positive patients, resulting in slower disease progression to aids and death. However the potential of drug interactions is high because of the drug-transporting P-glycoprotein and cytochrome P450 3A4-mediated metabolism. Administration of protease inhibitors may result in increased or decreased concentrations of co-administered drugs, and the plasma concentration of protease inhibitors may be affected by other drugs. It is possible to take advantage of the interactions by combining two protease inhibitors. Attention is drawn to the protease inhibitors and their possible interactions because of the advantages and disadvantages this implies. It is possible to monitor interactions by measuring plasma concentrations of the protease inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0034726527&partnerID=8YFLogxK

M3 - Review

C2 - 10986900

AN - SCOPUS:0034726527

VL - 162

SP - 4677

EP - 4681

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 35

ER -